The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: A systematic review and meta-analysis

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

“…Low/negative expression of ERCC1 was associated with longer OS and PFS in patients treated with cisplatin-based CRT, but there was no significant difference in ORR between low/negative and high/positive ERCC1 expression [17]. What are differences and similarities between these two meta-analyses and our metaanalysis?…”

“…Xuelei et al [16] included in their meta-analysis all studies irrespective of treatment modality, while Gao et al [17] included studies dealing with cisplatin-based chemoradiotherapy. We included all the studies with treatments containing platinum-based chemotherapy.…”

“…In an attempt to address this issue two meta-analyses has been published, one in the patients with HNSCC irrespective of the treatment modalities [16] and one in the patients treated with cisplatin-based concurrent CRT [17]. Since cisplatin-based chemotherapy is the part of different treatment modalities in patients with HNSCC we performed a systemic review and meta-analysis of studies outcomes to evaluate the prognostic and predictive value of ERCC1 expression in this category of patients.…”

“…Probably, high heterogeneity (I 2 = 80.5%) of the mixed head and neck cancer group was responsible for the lack of the association between ERCC1 expression and OS in that group. Gao et al [17] also reported that ERCC1 expression was a predictor of OS in patients with nasopharyngeal carcinoma.…”

“…Although sharing some similarities with the meta-analysis of Gao et al [17] our analysis of adjusted OS estimates included larger sample size of 940 patients from 15 studies while the study of Gao et al [17] included 568 patients from 9 studies.…”